China Biosimilars Market Size & Share 2026-2035

China Biosimilars Market Size

The China biosimilars market was valued at USD 4.6 billion in 2025. The market is estimated to grow from USD 5.5 billion in 2026 to USD 23.6 billion in 2035, growing at a CAGR of 17.5% over the analysis period, according to the latest report published by Global Market Insights Inc. The market is witnessing strong expansion, primarily stimulated by the rising demand for cost-effective biologic therapies and the increasing prevalence of chronic and complex diseases across the country.

China’s large population base, rapid urbanization, and growing burden of diseases such as cancer, diabetes, autoimmune disorders, and inflammatory conditions are significantly increasing the demand for biologic treatments. The expanding patient population requiring long-term therapy is creating sustained demand for affordable treatment alternatives, making biosimilars a critical component of the healthcare system. Additionally, supportive government policies, inclusion of biologics under reimbursement frameworks, and ongoing healthcare reforms aimed at improving affordability and accessibility are further accelerating the adoption of biosimilars across hospitals, specialty clinics, and outpatient care settings.

Biosimilars are highly similar versions of approved biologic medicines that demonstrate comparable safety, efficacy, and quality profiles to reference biologics while offering significantly lower treatment costs. In China, biosimilars play a crucial role in improving patient access to complex biologic therapies that were previously limited due to high costs. These therapies have emerged as critical alternatives for managing chronic and life-threatening diseases requiring complex biologic interventions, thereby expanding patient access and helping reduce treatment disparities across healthcare systems. Biosimilars undergo extensive analytical, clinical, and regulatory evaluations to establish biosimilarity and therapeutic equivalence with originator biologics.

Key players operating in the China biosimilars market include Innovent Biologics, Hengrui Medicine, BeiGene, Junshi Biosciences, Akeso, and RemeGen. While these companies are widely recognized for their innovative drug pipelines, they are also actively involved in the development and commercialization of biosimilars, particularly in monoclonal antibodies and oncology-related biologics. Their strategies focus on portfolio expansion, manufacturing scale-up, and improving accessibility of biologic therapies within China. At the same time, several of these companies are expanding internationally, with biosimilar products being introduced into Asia and increasingly targeting regulatory approvals in Europe and other global markets. This combination of innovation-led growth and biosimilar expansion is positioning these players as important contributors to the evolving biopharmaceutical landscape.

The market has increased from USD 2.5 billion in 2022 to USD 3.8 million in 2024, growing at a steady historical CAGR of 22.3%, supported by an increasing number of product approvals, expansion of domestic manufacturing capabilities, and rising investments in biologics development. Greater physician acceptance, improved patient awareness, and enhanced access through reimbursement channels contributed to the wider adoption of biosimilars across therapeutic areas such as oncology, autoimmune diseases, and metabolic disorders.

Furthermore, advancements in bioprocessing technologies, optimization of production infrastructure, and strengthening of supply chain networks have improved manufacturing efficiency and product availability, supporting the continued expansion of the biosimilars market in China.

China Biosimilars Market Trends

The China biosimilars market is witnessing strong growth as healthcare authorities and providers increasingly prioritize cost-effective alternatives to high-cost biologic therapies. Government initiatives focused on improving drug affordability, along with the expansion of national reimbursement programs and centralized procurement systems, are accelerating biosimilar adoption across public hospitals and healthcare institutions.

• A growing number of biologic drugs in China are approaching or have reached patent expiration, creating significant opportunities for domestic biosimilar manufacturers. This has enabled rapid entry of locally developed biosimilars, increased competition, and expanded treatment availability across key therapeutic areas such as oncology and autoimmune diseases.
• Further, the rising burden of chronic diseases in China, including cancer, diabetes, and autoimmune conditions, is significantly driving demand for biologic therapies and biosimilars. The expanding patient population requiring long-term treatment is reinforcing the need for affordable therapeutic options, supporting sustained biosimilar uptake across the healthcare system.
• Increasing physician and patient confidence in biosimilars is contributing to higher adoption rates across China. Growing clinical experience, improved regulatory standards, and wider hospital-level usage are strengthening trust in the safety, efficacy, and interchangeability of biosimilar products.
• Also, regulatory advancements by the National Medical Products Administration (NMPA) are transforming the biosimilar development landscape. The introduction of structured approval pathways, improved evaluation standards, and alignment with regulatory practices are helping reduce development timelines and support faster commercialization of biosimilar products.
• Additionally, expansion of domestic biomanufacturing capabilities and continuous investments in large-scale production facilities are enhancing China’s biosimilar supply capacity. Improvements in manufacturing efficiency, process optimization, and supply chain infrastructure are enabling cost-effective production and broader market accessibility.
• Government-driven healthcare reforms, including volume-based procurement (VBP) programs, are significantly influencing biosimilar market dynamics in China. These initiatives are driving price reductions, increasing competition, and encouraging the adoption of biosimilars to improve patient access and reduce overall healthcare expenditure.

China Biosimilars Market Analysis

Based on the product, the China biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and other products. The recombinant glycosylated proteins segment has asserted its dominance in the market by securing a significant market share of 65.3% in 2025, owing to the widespread use of glycosylated biologics such as monoclonal antibodies and erythropoietin drugs in the treatment of high-burden diseases. The segment is expected to exceed USD 15.3 billion by 2035, growing at a CAGR of 17.4% during the forecast period.     

• Recombinant glycosylated proteins, including monoclonal antibodies and erythropoietin-based therapies, are widely used in high-burden therapeutic areas such as oncology, anemia, and autoimmune diseases, driving strong demand across China’s healthcare system. Their clinical importance in treating complex and chronic conditions has significantly increased their adoption across hospitals and specialty care centers.
• The availability of multiple approved biosimilars for high-value glycosylated biologics, along with expanding domestic manufacturing capabilities, has strengthened the segment’s dominance. Additionally, favorable reimbursement policies, increased hospital procurement under centralized purchasing programs, and growing physician confidence have further accelerated the uptake of glycosylated protein biosimilars in China.
• The recombinant non‑glycosylated proteins segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 17.7% over the forecast period. The segment is driven by the widespread use of insulin, growth hormone, and interferon therapies in managing chronic conditions such as diabetes and hormonal disorders, supported by a large patient base requiring long-term treatment.

Based on application, the China biosimilars market is divided into hematology, oncology, autoimmune disease, ophthalmology, growth hormone deficiency, diabetes, and other applications. The hematology segment is further divided into neutropenia, anemia, and other hematology applications. The hematology segment dominated the market with a revenue share of 31.8% in 2025 and is expected to reach USD 7.3 billion within the forecast period.     

• The growth of the segment is seen due to the high prevalence of hematological conditions in China, particularly anemia associated with chronic kidney disease and oncology treatments. The demand for erythropoietin and related biosimilars remains significantly high, contributing to the dominance of the hematology segment. The increasing number of patients undergoing long-term therapies such as dialysis and chemotherapy further reinforces the necessity for cost-effective biologic alternatives.
• Additionally, the widespread availability of approved biosimilars for hematology indications, supported by strong domestic manufacturing and inclusion in reimbursement programs, has accelerated their adoption across hospitals and specialty care centers. Growing clinical acceptance and standardized treatment protocols are further strengthening the position of hematology as the leading application segment in the China biosimilars market.
• The oncology segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 18.1% over the forecast period. The segment is driven by increasing cancer prevalence and rising adoption of monoclonal antibody biosimilars for targeted therapies.
• The autoimmune disease segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 17.8% over the forecast period. Growth is supported by increasing use of biosimilars in conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.
• The ophthalmology segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 16.8% over the forecast period. The segment is driven by the rising prevalence of retinal disorders and increasing demand for biologic therapies in eye care.
• The growth hormone deficiency segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 16.4% over the forecast period. Growth is supported by increasing diagnosis rates and demand for long-term hormone replacement therapies.
• The diabetes segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 17.6% over the forecast period. The segment is driven by the large diabetic population in China and increasing demand for insulin biosimilars.

Based on manufacturing type, the China biosimilars market is divided into contract research and manufacturing services, and in-house. The in-house segment dominated the market in 2025 with USD 2.8 billion.     

• The dominance of in-house manufacturing is driven by the strong presence of vertically integrated biopharmaceutical companies, which prioritize internal production capabilities to ensure consistent quality, regulatory compliance, and better control over complex biologics manufacturing processes.
• Furthermore, significant investments in large-scale domestic manufacturing infrastructure and bioprocessing capabilities enable companies to achieve cost efficiencies, faster time-to-market, and improved supply chain reliability, reinforcing the preference for in-house production across the biosimilars industry in China.
• The contract research and manufacturing services segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 17.7% over the forecast period. The segment is driven by increasing outsourcing trends, particularly among emerging biotech firms seeking cost-efficient development and production capabilities without large capital investments.

Based on technology, the China biosimilars market is divided into recombinant DNA technology, mammalian cell culture systems, and other technologies. The recombinant DNA technology segment dominated the market in 2025, growing at a CAGR of 17.5% during the forecast period.     

• The recombinant DNA technology segment dominance is attributed to its broad applicability across a wide range of biosimilar molecules, particularly recombinant proteins such as insulin, interferons, and growth hormones. Its established scientific framework and standardized production processes have enabled consistent replication of reference biologics, making it the most widely utilized platform in biosimilar development.
• In addition, the strong adoption of recombinant-based platforms across China’s biosimilar pipeline, coupled with accumulated technical expertise and widespread integration in biologics development programs, continues to support its leading position. Technology’s adaptability across multiple therapeutic categories further enhances its relevance in the evolving biosimilars landscape.
• The mammalian cell culture systems segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 17.8% over the forecast period. The segment is driven by increasing demand for complex biologics such as monoclonal antibodies that require advanced expression systems for accurate protein structure and functionality.  

Based on distribution channel, the China biosimilars market is divided into hospital pharmacies, specialty pharmacies, and other distribution channels. The hospital pharmacies segment dominated the market in 2025 with a market share of 56.1%.       

• Hospital-based distribution remains central to biosimilar access in China, as most biologic therapies are initiated and managed within tertiary hospitals where specialist consultation, infusion infrastructure, and clinical monitoring are available. This concentration of treatment delivery reinforces hospitals as the primary point of access for biosimilars.
• The integration of procurement mechanisms and reimbursement systems within hospital networks further strengthens their role, as large volumes of biosimilars are supplied through institutional purchasing channels, ensuring consistent demand and structured supply across major healthcare facilities.
• The specialty pharmacies segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 17.8% over the forecast period. The segment is driven by increasing demand for specialized handling, patient support services, and distribution of complex biologics requiring controlled storage and administration.

China Biosimilars Market Share

The China biosimilars market is moderately competitive, characterized by the presence of established domestic biopharmaceutical players alongside emerging biologics manufacturers. Companies compete on product portfolio depth, pricing competitiveness, manufacturing capabilities, and alignment with government procurement systems, while strengthening their presence across hospital networks and public healthcare institutions. Key players include Shanghai Henlius Biotech, Bio‑Thera Solutions, Innovent Biologics, 3SBio, and Qilu Pharmaceutical, collectively accounting for ~58% of the total market share.

Market participants are increasingly focusing on expanding their biosimilar portfolios through continuous pipeline development, targeting high-value biologics such as monoclonal antibodies and insulin products. Strategic initiatives such as capacity expansion, domestic partnerships, and participation in centralized procurement programs are intensifying competition and strengthening market positioning across China’s evolving biosimilars landscape.

China Biosimilars Market Companies

Major players operating in the China biosimilars industry are:

• 3SBio
• Akeso
• BeiGene
• Bio-Thera Solutions
• Gan & Lee Pharmaceuticals
• Hengrui Medicine
• Hisun Pharmaceutical
• Innovent Biologics
• Junshi Biosciences
• Mabwell Bioscience
• Qilu Pharmaceutical
• RemeGen
• Shanghai Henlius Biotech
• Tonghua Dongbao Pharmaceutical
   

• Shanghai Henlius Biotech is a leading biosimilars player in China with a strong monoclonal antibody portfolio and advanced manufacturing capabilities, enabling large-scale commercial supply across key therapeutic areas such as oncology and immunology. For example, its biosimilar HANLIKANG (rituximab) was the first approved biosimilar in China, followed by products such as HANQUYOU (trastuzumab) and HANBEITAI (bevacizumab), which have strengthened its position by providing cost-effective alternatives to high-value biologics while maintaining comparable clinical efficacy.

• Bio‑Thera Solutions is a prominent biosimilars developer with a diversified pipeline targeting high-value biologic molecules and strong in-house R&D capabilities, supporting rapid product development and commercialization within China. For example, its biosimilar Qletli (adalimumab) was among the first approved adalimumab biosimilars in China, along with additional biosimilars such as bevacizumab and tocilizumab, enabling broader patient access to affordable treatments for autoimmune and oncology conditions while maintaining quality and safety standards.

China Biosimilars Industry News

• In May 2026, Shanghai Henlius received NMPA approval for its pertuzumab biosimilar, further strengthening its oncology biosimilars portfolio. The approval supports broader access to cost-effective HER2-targeted therapies for breast cancer treatment while reinforcing Henlius’s leadership in China’s biosimilars market.
• In August 2025, China’s National Medical Products Administration (NMPA) approved the world’s first dulaglutide biosimilar developed by Boan Biotech, marking a significant expansion of biosimilars into the metabolic disease segment. The approval aims to improve patient access to cost-effective diabetes therapies while strengthening China’s position as a global innovator in biosimilar development.
• In December 2025, Fresenius Kabi launched its denosumab biosimilars in Europe, expanding its biosimilars portfolio in bone health and oncology. The launch aims to improve patient access to cost-effective therapies while strengthening the company’s presence in the European biologics market.
• In November 2023, Sandoz launched its adalimumab biosimilar Hyrimoz in additional markets, expanding access to affordable autoimmune therapies. The launch strengthened Sandoz’s immunology portfolio and supported broader patient adoption through competitive pricing strategies.

The China biosimilars market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Recombinant non-glycosylated proteins 
  • Human growth hormone
  • Granulocyte colony-stimulating factor (filgrastim)
  • Insulin
  • Interferon
    • Alfa
    • Beta
• Recombinant glycosylated proteins 
  • Monoclonal antibodies 
    • Infliximab
    • Rituximab
    • Adalimumab
    • Trastuzumab
    • Bevacizumab
  • Erythropoietin
    • Alfa
    • Beta
  • Follitropin
    • Alfa
    • Beta
  • Fusion proteins
• Other products

Market, By Application

• Hematology            
  • Neutropenia  
  • Anemia        
  • Other hematology applications       
• Oncology      
  • Lung cancer  
  • Brain cancer 
  • Breast cancer
  • Cervical cancer       
  • Colorectal cancer     
  • Leukemia      
  • Other Oncology applications
• Autoimmune disease          
  • Arthritis        
    • Rheumatoid arthritis
    • Psoriatic arthritis
    • Juvenile arthritis
    • Ankylosing spondylitis
    • Other arthritis
  • Inflammatory bowel disease (IBD) 
    • Ulcerative colitis
    • Crohn's disease
    • Other IBD
  • Psoriasis       
  • Other autoimmune diseases
• Ophthalmology                 
• Growth hormone deficiency           
• Diabetes                
• Other applications              

Market, By Manufacturing Type

• Contract research and manufacturing services
• In-house

Market, By Technology

• Recombinant DNA technology
• Mammalian cell culture systems
• Other technologies

Market, By Distribution Channel

• Hospital Pharmacies 
• Specialty Pharmacies
• Other distribution channels